Analyst Ratings for Day One Biopharmaceutical
Portfolio Pulse from Benzinga Insights
Analysts have provided ratings for Day One Biopharmaceutical (NASDAQ:DAWN) in the last quarter, with 6 bullish, 1 somewhat bullish, and 1 somewhat bearish. The average 12-month price target is $38.75, a 9.36% decrease from the previous average of $42.75.
June 05, 2023 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One Biopharmaceutical has mostly bullish analyst ratings with an average 12-month price target of $38.75, representing a 9.36% decrease from the previous average.
The majority of analysts have a bullish outlook on Day One Biopharmaceutical, which is a positive sign for the stock. However, the decrease in the average 12-month price target suggests that there may be some uncertainty or potential downside in the short term. Overall, the impact on the stock is likely to be positive in the short term due to the predominantly bullish ratings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100